These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 31177992)
1. Total copy number variation as a prognostic factor in adult astrocytoma subtypes. Mirchia K; Sathe AA; Walker JM; Fudym Y; Galbraith K; Viapiano MS; Corona RJ; Snuderl M; Xing C; Hatanpaa KJ; Richardson TE Acta Neuropathol Commun; 2019 Jun; 7(1):92. PubMed ID: 31177992 [TBL] [Abstract][Full Text] [Related]
2. Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas. Richardson TE; Sathe AA; Xing C; Mirchia K; Viapiano MS; Snuderl M; Abdullah KG; Hatanpaa KJ; Walker JM J Neuropathol Exp Neurol; 2021 Mar; 80(4):354-365. PubMed ID: 33755138 [TBL] [Abstract][Full Text] [Related]
3. Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas. Mirchia K; Snuderl M; Galbraith K; Hatanpaa KJ; Walker JM; Richardson TE Acta Neuropathol Commun; 2019 Jul; 7(1):121. PubMed ID: 31349875 [No Abstract] [Full Text] [Related]
4. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas. Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296 [TBL] [Abstract][Full Text] [Related]
5. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156 [TBL] [Abstract][Full Text] [Related]
6. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas. Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613 [TBL] [Abstract][Full Text] [Related]
7. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667 [TBL] [Abstract][Full Text] [Related]
8. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459 [TBL] [Abstract][Full Text] [Related]
9. T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas. Lee MD; Jain R; Galbraith K; Chen A; Lieberman E; Patel SH; Placantonakis DG; Zagzag D; Barbaro M; Guillermo Prieto Eibl MDP; Golfinos JG; Orringer DA; Snuderl M Clin Cancer Res; 2024 Aug; 30(16):3512-3519. PubMed ID: 38829583 [TBL] [Abstract][Full Text] [Related]
10. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258 [TBL] [Abstract][Full Text] [Related]
11. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas. Galbraith K; Garcia M; Wei S; Chen A; Schroff C; Serrano J; Pacione D; Placantonakis DG; William CM; Faustin A; Zagzag D; Barbaro M; Eibl MDPGP; Shirahata M; Reuss D; Tran QT; Alom Z; von Deimling A; Orr BA; Sulman EP; Golfinos JG; Orringer DA; Jain R; Lieberman E; Feng Y; Snuderl M Neuro Oncol; 2024 Jun; 26(6):1042-1051. PubMed ID: 38243818 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas. Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198 [TBL] [Abstract][Full Text] [Related]
16. Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas. Richardson TE; Sathe AA; Kanchwala M; Jia G; Habib AA; Xiao G; Snuderl M; Xing C; Hatanpaa KJ J Neuropathol Exp Neurol; 2018 Jul; 77(7):542-548. PubMed ID: 29741737 [TBL] [Abstract][Full Text] [Related]
17. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma. Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258 [TBL] [Abstract][Full Text] [Related]
18. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668 [TBL] [Abstract][Full Text] [Related]
19. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492 [TBL] [Abstract][Full Text] [Related]
20. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]